ClinicalTrials.gg

Program

Sutantatug Envedotin

Also written as “SYS6002” and “CRB-701”.

Its studies are mostly in Oropharyngeal Neoplasms · Carcinoma, Transitional Cell · Uterine Cervical Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Furthest: phase 3, since Nov 13, 20256 company-led studies, 6 open or runningNext primary completion: Jan 16, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group44 open or runningphase 3since Nov 13, 2025Apr 25, 2025Dec 30, 2027phase 2 · NCT06989671
Corbus Pharmaceuticals22 open or runningphase 3since Aug 12, 2026Feb 8, 2024Jan 16, 2027phase 2 · NCT06265727

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 8, 2024First study: phase 2 study in Solid Tumor, AdultNew to Corbus PharmaceuticalsCorbus Pharmaceuticals · NCT06265727 · 348 planned · United States, France, Italy and more
  2. Apr 25, 2025CSPC Pharmaceutical Group’s first study: phase 2 study in Squamous Cell Carcinoma of Head and NeckNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06989671 · 430 planned
  3. Nov 13, 2025Phase 3 study in Uterine Cervical NeoplasmsCSPC Pharmaceutical Group · NCT07230626 · 412 planned
  4. Jan 21, 2026Phase 2 study in Advanced Urothelial CarcinomaCSPC Pharmaceutical Group · NCT07374549 · 100 planned
  5. Apr 7, 2026Phase 3 study in Carcinoma, Transitional CellCSPC Pharmaceutical Group · NCT07526792 · 406 planned
  6. Aug 12, 2026Phase 3 study in Oropharyngeal NeoplasmsPhase 3 reachedCorbus Pharmaceuticals · NCT07768189 · 260 planned · United States, Austria, Belgium and more

Ahead

  1. Jan 16, 2027Primary completion: phase 2 study in Solid Tumor, AdultCorbus Pharmaceuticals · NCT06265727
  2. Dec 2027Primary completion: phase 3 study in Oropharyngeal NeoplasmsCorbus Pharmaceuticals · NCT07768189
  3. Dec 30, 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckCSPC Pharmaceutical Group · NCT06989671
  4. Jan 1, 2028Primary completion: phase 3 study in Uterine Cervical NeoplasmsCSPC Pharmaceutical Group · NCT07230626

TargetBeta

NECTIN4 →read by rule
“An antibody-drug conjugate (ADC) composed of sutantatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4), site-specifically ”NCIt, by rule

Other programs on NECTIN4

ProgramCompanyFurthest phaseStudies
enfortumab vedotinruleAstellas Pharmaphase 420
notiretatug rezetecanJiangsu HengRui Medicinephase 314
bulumtatug fuvedotinruleMabwell (Shanghai) Biosciencephase 313
zelenectide pevedotinrulebicycletx-limitedphase 25
Anti-nectin-4 Antibody-drug Conjugate MK-3120ruleMerckphase 25
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-nectin-4 Antibody-drug Conjugate IPH4502ruleinnate-pharmaphase 11
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rulerondo-therapeuticsphase 11
CT-202rulecontext-therapeutics-incphase 11

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07768189Oropharyngeal Neoplasms · United States, Austria, Belgium and more3RecruitingCorbus PharmaceuticalsDec 2027260
NCT07526792Carcinoma, Transitional Cell3Not yet recruitingCSPC Pharmaceutical GroupJun 1, 2029406
NCT07374549Advanced Urothelial Carcinoma2Not yet recruitingCSPC Pharmaceutical GroupJun 1, 2028100
NCT07230626Uterine Cervical Neoplasms3Not yet recruitingCSPC Pharmaceutical GroupJan 1, 2028412
NCT06989671Squamous Cell Carcinoma of Head and Neck2Not yet recruitingCSPC Pharmaceutical GroupDec 30, 2027430
NCT06265727Solid Tumor, Adult · United States, France, Italy and more2RecruitingCorbus PharmaceuticalsJan 16, 2027348

How it is read

Names in the registry

  • “SYS6002”, 4 entries
  • “CRB-701”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.